GSK2820151 / GSK - LARVOL DELTA

Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - P1; N=5; Terminated; Sponsor: GlaxoSmithKline; Trial completion date: May 2019 ➔ Dec 2018; Active, not recruiting ➔ Terminated; Trial primary completion date: May 2019 ➔ Dec 2018; In 2017, GSK2820151 was terminated due to development of another BET Inhibitor (GSK525762) with a better understanding of the risk benefit profile.

Trial completion date • Trial primary completion date • Trial termination